Zhang Chunyu, Yin Xiaoguang, Zhang Jinghan, Ao Qiang, Gu Yongquan, Liu Ying
Department of Respiratory Medicine, Siping Hospital of China Medical University, Siping, Jilin 136000, P.R. China.
Jilin Tuhua Bioengineering Co., Ltd., Siping, Jilin 136000, P.R. China.
Exp Ther Med. 2017 May;13(5):1922-1926. doi: 10.3892/etm.2017.4222. Epub 2017 Mar 10.
Idiopathic pulmonary fibrosis (IPF) is a degenerative disease characterized by fibrosis. Cell therapy has been considered within the therapeutic options for IPF. In this study, we explored the potential benefits of human umbilical cord-derived mesenchymal stem cell (HUC-MSC) intravenous infusion in the management of IPF. We describe a case of a 56-year-old man with IPF who was receiving long-term oxygen therapy (LTOT). The patient underwent HUC-MSC intravenous infusion and was followed up for 12 months. Clinical and motor tests, as well as questionnaires assessing quality of life, were performed prior to and following the transplantation. At the end of 12 months, a relevant reduction of LTOT requirement was registered; improvements in terms of physical performance, quality of life, and respiratory parameters were observed in our patient. In conclusion, a program of HUC-MSC intravenous infusion appears to be beneficial to patients with IPF and may be considered as an additional therapeutic option.
特发性肺纤维化（IPF）是一种以纤维化为特征的退行性疾病。细胞疗法已被纳入IPF的治疗选择之中。在本研究中，我们探讨了人脐带间充质干细胞（HUC-MSC）静脉输注在IPF治疗中的潜在益处。我们描述了一例56岁患有IPF且正在接受长期氧疗（LTOT）的男性病例。该患者接受了HUC-MSC静脉输注，并进行了12个月的随访。在移植前后进行了临床和运动测试，以及评估生活质量的问卷调查。在12个月末，记录到LTOT需求有显著降低；我们的患者在身体机能、生活质量和呼吸参数方面均有改善。总之，HUC-MSC静脉输注方案似乎对IPF患者有益，可被视为一种额外的治疗选择。
